BRIEF published on 05/08/2026 at 22:35, 14 days 1 hour ago Integrated BioPharma annonce une baisse de son chiffre d'affaires trimestriel Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Fabrication Sous Contrat
BRIEF published on 05/08/2026 at 22:35, 14 days 1 hour ago Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
PRESS RELEASE published on 05/08/2026 at 22:30, 14 days 1 hour ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRIEF published on 02/11/2026 at 22:35, 3 months 11 days ago Integrated BioPharma annonce ses résultats financiers du quatrième trimestre 2025 Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Dépendance Du Client
BRIEF published on 02/11/2026 at 22:35, 3 months 11 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 3 months 11 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 6 months 12 days ago Integrated BioPharma publie ses résultats financiers pour le troisième trimestre 2025 Résultats Financiers Baisse Des Revenus Résultat D'exploitation Revenu Net Fabrication Sous Contrat
BRIEF published on 11/10/2025 at 21:55, 6 months 12 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 6 months 12 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 7 months 29 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
Published on 05/23/2026 at 00:15, 6 minutes ago Molten Metals Completes Airborne Geophysical Survey at Texas Project
Published on 05/23/2026 at 00:00, 21 minutes ago Redwood AI Announces Collaboration with Resilience Biosciences Inc. to Advance AI-Assisted Small-Molecule Drug Development
Published on 05/22/2026 at 14:04, 10 hours 17 minutes ago Wi2Wi Corporation Announces First Quarter 2026 Financial Results (Unaudited)
Published on 05/22/2026 at 22:05, 2 hours 16 minutes ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 2 hours 16 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 4 hours 30 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 5 hours 48 minutes ago Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 5 hours 51 minutes ago Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Published on 05/22/2026 at 19:35, 4 hours 46 minutes ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 6 hours 16 minutes ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 6 hours 16 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 11 hours 29 minutes ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 11 hours 29 minutes ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
